Curi Bio
Curi Bio integrates human stem cells, systems, and AI-enabled data analytics for the development of new therapeutics.
About Curi Bio
Curi Bio is a biotechnology company that focuses on advancing drug discovery and development through innovative approaches involving human stem cells, systems biology, and data analytics. The company's primary goal is to accelerate the process of identifying and developing new medicines. Curi Bio's platform revolves around the use of human stem cells, which have the potential to be differentiated into various cell types, replicating the behavior of different tissues and organs. This allows researchers to create more accurate and relevant models for studying disease mechanisms and testing potential drug candidates. NanoSurface Biomedical Is Now Curi Bio.
Company Facts
- Headquarters
- Seattle
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $30,400,000
- Last Funding Type
- series_b
- Last Funding Date
- 2025-12-02
- Website
- curibio.com
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Medical, Service Industry
Social Links
Canonical: https://fsome.com/organization/curi-bio-48338 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.